Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Website: bms.com


  • Good financial results growth rate 19.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-6.8%)
  • Dividend yield for the last twelve months 5.5%
  • Free cash flow yield 10.0% (LTM)
  • Share price is 13.5% higher than minimum and 44.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (20.0x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BMY
Share price, USD:  (+0.1%)45.015
year average price 52.53  


year start price 50.94 2024-09-24

max close price 63.11 2025-03-10

min close price 43.31 2025-07-31

current price 45.02 2025-09-23
Common stocks: 2 111 517 922

Dividend Yield:  5.5%
FCF Yield LTM: 10.0%
EV / LTM EBITDA: 20.0x
EV / EBITDA annualized: 18.6x
Last revenue growth (y/y):  +0.6%
Last growth of EBITDA (y/y):  +37.9%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -14.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 95 050
Net Debt ($m): 36 640
EV (Enterprise Value): 131 690
EBITDA LTM ($m): 6 595
EV / LTM EBITDA: 20.0x
Price to Book: 5.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-23seekingalpha.com

Bristol-Myers Squibb Company (BMY) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

2025-09-23forbes.com

Buy Bristol Myers Squibb Stock At $45?

2025-09-23fool.com

1 Reason to Buy Bristol Myers Squibb Stock

2025-09-20seekingalpha.com

Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income

2025-09-19zacks.com

Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?

2025-09-17reuters.com

Bristol Myers to sell 60% stake in China joint venture

2025-09-09zacks.com

Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know

2025-09-08benzinga.com

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

2025-09-08seekingalpha.com

Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

2025-09-08reuters.com

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data